Hikma Pharmaceuticals PLC (LON: HIK)

Market Cap	4.39B
Revenue (ttm)	2.26B
Net Income (ttm)	149.55M
Shares Out	221.89M
EPS (ttm)	0.67
PE Ratio	29.52
Forward PE	11.35
Dividend	0.72 (3.64%)
Ex-Dividend Date	Mar 21, 2024

Volume	219,722
Open	1,983.00
Previous Close	1,983.00
Day's Range	1,969.00 - 1,991.00
52-Week Range	1,711.00 - 2,222.00
Beta	0.44
Analysts	n/a
Price Target	23.19 (-98.83%)
Earnings Date	Feb 22, 2024

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various th...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Country: United Kingdom
• Stock Exchange: London Stock Exchange
• Ticker Symbol: HIK

Financial Performance

In 2023, HIK's revenue was $2.88 billion, an increase of 14.22% compared to the previous year's $2.52 billion. Earnings were $190.00 million, an increase of 1.06%.

Financial numbers in USD